Compare HY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | ADCT |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.5M | 439.8M |
| IPO Year | N/A | 2020 |
| Metric | HY | ADCT |
|---|---|---|
| Price | $33.41 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 88.2K | ★ 565.6K |
| Earning Date | 02-24-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $3,913,600,000.00 | $75,209,000.00 |
| Revenue This Year | N/A | $12.48 |
| Revenue Next Year | N/A | $5.12 |
| P/E Ratio | $218.68 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $26.41 | $1.05 |
| 52 Week High | $57.89 | $4.80 |
| Indicator | HY | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 46.33 |
| Support Level | $32.27 | $3.48 |
| Resistance Level | $35.08 | $3.87 |
| Average True Range (ATR) | 1.36 | 0.21 |
| MACD | 0.16 | 0.02 |
| Stochastic Oscillator | 64.44 | 37.25 |
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).